<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46331">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503085</url>
  </required_header>
  <id_info>
    <org_study_id>NL1304</org_study_id>
    <nct_id>NCT02503085</nct_id>
  </id_info>
  <brief_title>Ibuprofen Suspension Bioequivalence Study</brief_title>
  <official_title>A Randomised, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic Study Comparing a 2% (w/v) Suspension of Ibuprofen (400 mg/20 ml) With a Reference 2% (w/v) Suspension of Ibuprofen (400 mg/20 ml) in the Fed and Fasted States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reckitt Benckiser Healthcare (UK) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reckitt Benckiser Healthcare (UK) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the rate and extent of absorption of Ibuprofen
      suspension formulations.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Endpoint is the pharmacokinetic parameters Area Under Curve 0-time and Concentration maximum which are derived from the plasma ibuprofen concentrations of the two ibuprofen formulations</measure>
    <time_frame>0-4 hours</time_frame>
    <description>The primary outcome measure is a composite</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>K elimination - Elimination Rate Constant</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve - Ratio AUC0-4 / AUC0-inf</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Area Under Curves at each blood sampling time point up to 90 minutes.</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time max - Time until Cmax is first achieved</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time 1/2 - Plasma concentration half-life</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration - The plasma concentration at each planned nominal time-point</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed in terms of the overall proportion of subjects with adverse events (AEs).</measure>
    <time_frame>0-4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy Volunteer Study</condition>
  <arm_group>
    <arm_group_label>Ibuprofen Suspension (fed/fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No intervention required</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibuprofen Suspension (fed\fasted)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No intervention required</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen Suspension</intervention_name>
    <arm_group_label>Ibuprofen Suspension (fed/fasted)</arm_group_label>
    <arm_group_label>Ibuprofen Suspension (fed\fasted)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have given written informed consent.

          -  Age: ≥ 18 years ≤ 50 years.

          -  Sex: Male or female subjects are eligible for entry.

          -  Female subject of child bearing potential with a negative pregnancy test at the
             screening visit and willing to use an effective method of contraception, if not of
             child bearing potential

          -  Male subject willing to use an effective method of contraception, unless anatomically
             sterile

          -  Status: healthy subjects as determined by past medical history, physical examination,
             vital signs, electrocardiogram, and laboratory tests at screening.

          -  Healthy Subjects with a Body Mass Index (BMI) of ≥18 and ≤30 kg/m2

        Exclusion Criteria:

          -  Pregnancy or lactating female subjects.

          -  A history of significant disease of any body system.

          -  Any condition that may currently interfere with the absorption, distribution,
             metabolism or excretion of drugs.

          -  A history of allergy or intolerance related to treatment with ibuprofen, aspirin or
             other Non-Steroidal Anti-inflammatory Disease,or the excipients of the formulations.

          -  A history of or active peptic or duodenal ulcers or gastro-intestinal bleed or upper
             gastro-intestinal bleed, or other significant gastro-intestinal disorders.

          -  A history of frequent dyspepsia, e.g. heartburn or indigestion.

          -  A history of migraine.

          -  A history of psychotic illness, attempted suicide or parasuicide.

          -  Current smokers and ex-smokers who have smoked within 6 months.

          -  A history of drug abuse (including alcohol).

          -  High consumption of stimulating drinks (caffeine intake per day above 300 mg).

          -  Those with positive drugs of abuse screen including alcohol on any occasion
             throughout the study.

          -  Ingestion of a prescribed drug at any time in the 14 days before dosing with study
             medication (excluding hormonal contraceptives and hormone replacement therapy), or
             consumption of enzyme inhibitors or inducers during the previous month (such as
             barbiturates, carbamazepine, erythromycin, phenytoin, etc.).

          -  Ingestion of an over-the-counter preparation within 7 days before dosing with study
             medication.

          -  Donation of blood in quantity in the previous 12 weeks before enrolment into the
             study.

          -  Known human immune deficiency virus (HIV) positive status, or a positive viral
             serology screen.

          -  Topical use of ibuprofen within 7 days before dosing with study medication.

          -  Those previously randomised into this study.

          -  Employee at study site.

          -  Partner or first degree relative of the Investigator.

          -  Those who have participated in a clinical trial in the previous 12 weeks.

          -  Those unable in the opinion of the Investigator to comply fully with the study
             requirements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Reckit Benckiser</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>May 27, 2016</lastchanged_date>
  <firstreceived_date>July 13, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
